Edition:
India

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

60.14USD
14 Nov 2018
Change (% chg)

-- (--)
Prev Close
$60.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
124,425
52-wk High
$99.26
52-wk Low
$19.32

Latest Key Developments (Source: Significant Developments)

Reata Pharma Announces Positive Phase 2 Data For Bardoxolone Methyl
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES POSITIVE PHASE 2 DATA FOR BARDOXOLONE METHYL IN IGA NEPHROPATHY AND TYPE 1 DIABETIC CHRONIC KIDNEY DISEASE.REATA PHARMACEUTICALS - STATISTICALLY SIGNIFICANT IMPROVEMENT IN KIDNEY FUNCTION OBSERVED IN BOTH DISEASES AFTER 12 WEEKS OF TREATMENT.REATA PHARMACEUTICALS - WITH RESPECT TO SAFETY, NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED IN EITHER COHORT.  Full Article

Reata Pharmaceuticals Reports Q2 Loss Per Share Of $1.08
Thursday, 9 Aug 2018 

Aug 8 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS.Q2 LOSS PER SHARE $1.08.Q2 EARNINGS PER SHARE VIEW $-0.73 -- THOMSON REUTERS I/B/E/S.  Full Article

Reata Announces Positive Phase 2 Data For Bardoxolone Methyl In CKD
Monday, 23 Jul 2018 

July 23 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES POSITIVE PHASE 2 DATA FOR BARDOXOLONE METHYL IN CKD CAUSED BY ALPORT SYNDROME AND AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE.REATA PHARMACEUTICALS INC - STATISTICALLY SIGNIFICANT IMPROVEMENT IN KIDNEY FUNCTION OBSERVED IN ADPKD PATIENTS AFTER 12 WEEKS OF TREATMENT.REATA PHARMACEUTICALS INC - STATISTICALLY SIGNIFICANT RETAINED BENEFIT OF 4.1 ML/MIN IN ALPORT SYNDROME PATIENTS FOLLOWING 48 WEEKS OF TREATMENT AND 4 WEEKS OF DRUG WITHDRAWAL.REATA PHARMACEUTICALS - STATISTICALLY SIGNIFICANT IMPROVEMENT IN KIDNEY FUNCTION MAINTAINED IN ALPORT SYNDROME PATIENTS AFTER 48 WEEKS OF TREATMENT.REATA PHARMACEUTICALS INC - REATA REPORTED POSITIVE ONE-YEAR RESULTS FOR PHASE 2 PORTION OF CARDINAL.REATA PHARMACEUTICALS - REPORTED POSITIVE FINAL RESULTS FOR PHASE 2 AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE COHORT OF PHOENIX.  Full Article

Reata Receives Orphan Drug Designation From The European Commission For Omaveloxolone
Wednesday, 11 Jul 2018 

July 10 (Reuters) - Reata Pharmaceuticals Inc ::REATA RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR OMAVELOXOLONE FOR THE TREATMENT OF FRIEDREICH’S ATAXIA.REATA PHARMACEUTICALS - CURRENTLY ENROLLING ABOUT 100 FA PATIENTS IN REGISTRATIONAL PART 2 PORTION OF PHASE 2 TRIAL MOXIE, AND SEES RESULTS IN H2 2019.  Full Article

Reata Announces Initiation Of Phase 1 Trial Of RTA 1701
Thursday, 21 Jun 2018 

June 20 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES INITIATION OF A PHASE 1 TRIAL OF RTA 1701, A SELECTIVE, ORAL ALLOSTERIC INHIBITOR OF RORΓT.REATA PHARMACEUTICALS INC - INITIAL RESULTS FROM RTA 1701 TRIAL ARE EXPECTED IN FIRST HALF OF 2019.REATA PHARMACEUTICALS INC - RTA 1701 DEMONSTRATED SIGNIFICANT EFFICACY AFTER ORAL DOSING IN RODENT MODELS OF RHEUMATOID ARTHRITIS & MULTIPLE SCLEROSIS.  Full Article

Reata Says Kyowa Hakko Kirin Initiated Ayame, A Phase 3 Trial Of Bardoxolone Methyl For The Treatment Of Diabetic Kidney Disease
Monday, 4 Jun 2018 

June 4 (Reuters) - Reata Pharmaceuticals Inc ::REATA ANNOUNCES THAT KYOWA HAKKO KIRIN INITIATED AYAME, A PHASE 3 TRIAL OF BARDOXOLONE METHYL FOR THE TREATMENT OF DIABETIC KIDNEY DISEASE.REATA PHARMACEUTICALS INC - ESTIMATED PHASE 3 STUDY COMPLETION DATE IS MARCH 2022.  Full Article

Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome
Thursday, 12 Apr 2018 

April 11 (Reuters) - Reata Pharmaceuticals Inc ::REATA PROVIDES UPDATE ON THE PHASE 2 PORTION OF THE CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME.IN STUDY, BARDOXOLONE TREATMENT PRODUCED "SIGNIFICANT" INCREASE IN KIDNEY FUNCTION MAINTAINED THROUGH WEEK 36.BARDOXOLONE CONTINUES TO BE WELL-TOLERATED IN ALPORT SYNDROME PATIENTS.ADVERSE EVENTS HAVE BEEN GENERALLY MILD TO MODERATE IN SEVERITY, NO DRUG-RELATED SERIOUS ADVERSE EVENTS BEEN REPORTED IN TRIAL.  Full Article

Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK).REATA SAYS THIRD SUPPLEMENT ALLOWS CO TO BEGIN PORTION OF PHASE 3 CLINICAL STUDY OF RTA 402 IN FIELD OF ALPORT SYNDROME IN JAPAN - SEC FILING.REATA PHARMACEUTICALS - ON DEC 7 CO ENTERED FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO & KHK.  Full Article

Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc ::Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing.  Full Article

Reata Pharmaceuticals Q3 loss per share $0.50
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results.Q3 loss per share $0.50.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Reata Pharmaceuticals Inc - qtrly ‍total collaboration revenue $12.6 million versus $12.6 million.Reata Pharmaceuticals Inc - ‍as of September 30, 2017, company had $154.6 million in cash and cash equivalents​.  Full Article